The following is a summary of the Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript:
Financial Performance:
Q4 revenue reached $24.6 billion, a 7.1% increase despite STELARA headwinds.
Full year 2025 worldwide sales were $94.2 billion, up 5.3%.
Q4 net earnings were $5.1 billion with diluted EPS of $2.10, an increase from $1.41 year-over-year.Full year net earnings were $26.8 billion with a diluted EPS of $11.03.
Business Progress:
Focus on six core areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision.
Investment of over $32 billion in R&D and M&A, including acquisitions and new manufacturing facilities.
Achievement of 51 approvals and 32 submissions across major markets in 2025.
Major growth in Oncology with DARZALEX sales over $14 billion and operational sales growth of 21% in 2025.
Financial Guidance:
Operational sales growth forecast for 2026 is 5.7% to 6.7%, with a midpoint of 6.2%.
Expectations for net interest expense between $300 million and $400 million for 2026.
Guidance for adjusted operational EPS growth of 5.5% at the midpoint, with an increase in diluted share count to about 2.44 billion shares.
Opportunities:
Continuing growth in Oncology, targeting $50 billion in sales by 2030.
Expected increased sales from TREMFYA, aiming for over $10 billion in peak year sales.
Launches in innovative Medicine and MedTech, including products like RYBREVANT and OTTAVA robotic surgical system.
Risks:
Market and competitive pressures, particularly noted in MedTech Surgery and Vision sectors.
Generic impacts anticipated for SIMPONI and OPSUMIT in 2026 discussed as part of full year guidance.
More details: Johnson & Johnson IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
